耐受性-话题@MedSci

#耐受性#

144篇内容 | 4024人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1417717, encodeId=5776141e717ab, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Ann Rheum Dis：尼达尼布对系统性硬化症相关性间质性肺病的安全性和耐受性, objectType=article, longId=199800, objectId=1f621998005a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f621998005a, replyNumber=0, likeNumber=78, createdTime=2020-08-23, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f621998005a, moduleTitle=Ann Rheum Dis：尼达尼布对系统性硬化症相关性间质性肺病的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f621998005a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417716, encodeId=7945141e71618, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性, objectType=article, longId=199228, objectId=6fe419922898, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fe419922898, replyNumber=0, likeNumber=65, createdTime=2020-08-13, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fe419922898, moduleTitle=Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fe419922898)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417715, encodeId=699b141e71568, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Adv Sci ：朱奎/沈建忠团队在抗菌药物耐受性形成机制上取得新进展, objectType=article, longId=198631, objectId=ec12198631f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec12198631f4, replyNumber=0, likeNumber=34, createdTime=2020-08-04, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec12198631f4, moduleTitle=Adv Sci ：朱奎/沈建忠团队在抗菌药物耐受性形成机制上取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec12198631f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417714, encodeId=3303141e71466, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet：蚊唾液疫苗耐受性及免疫原性研究, objectType=article, longId=196549, objectId=27f9196549d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f9196549d4, replyNumber=0, likeNumber=55, createdTime=2020-06-28, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f9196549d4, moduleTitle=Lancet：蚊唾液疫苗耐受性及免疫原性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f9196549d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417713, encodeId=2949141e713d9, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Ann Oncol：OlympiAD最终的总体存活率和耐受性结果, objectType=article, longId=195895, objectId=0f9419589573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9419589573, replyNumber=0, likeNumber=57, createdTime=2020-06-16, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9419589573, moduleTitle=Ann Oncol：OlympiAD最终的总体存活率和耐受性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9419589573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, objectType=article, longId=195323, objectId=989d195323d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989d195323d7, replyNumber=0, likeNumber=53, createdTime=2020-06-06, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989d195323d7, moduleTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989d195323d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417711, encodeId=fd6d141e711b1, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性, objectType=article, longId=192980, objectId=65b21929803d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65b21929803d, replyNumber=0, likeNumber=52, createdTime=2020-04-27, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65b21929803d, moduleTitle=Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65b21929803d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417710, encodeId=e3bf141e710ea, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, objectType=article, longId=192882, objectId=1354192882ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1354192882ef, replyNumber=0, likeNumber=68, createdTime=2020-04-25, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1354192882ef, moduleTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1354192882ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417709, encodeId=22ff141e709d8, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Prostate：镭223进行再治疗的耐受性良好, objectType=article, longId=192820, objectId=b368192820b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b368192820b3, replyNumber=0, likeNumber=57, createdTime=2020-04-24, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b368192820b3, moduleTitle=Prostate：镭223进行再治疗的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b368192820b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417708, encodeId=91bd141e708f0, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JAMA: 基孔肯雅病毒样颗粒疫苗的安全性和耐受性如何？, objectType=article, longId=192579, objectId=19451925e967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19451925e967, replyNumber=0, likeNumber=54, createdTime=2020-04-21, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19451925e967, moduleTitle=JAMA: 基孔肯雅病毒样颗粒疫苗的安全性和耐受性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19451925e967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417707, encodeId=33df141e7076d, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=EClinicalMedicine：含有贝达奎林和/或德拉米尼的无注射剂治疗方案对青少年有效且耐受性良好, objectType=article, longId=191906, objectId=8c981919067e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c981919067e, replyNumber=0, likeNumber=114, createdTime=2020-04-11, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c981919067e, moduleTitle=EClinicalMedicine：含有贝达奎林和/或德拉米尼的无注射剂治疗方案对青少年有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c981919067e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417706, encodeId=e3f4141e7061a, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析 , objectType=article, longId=191614, objectId=431c191614eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431c191614eb, replyNumber=0, likeNumber=37, createdTime=2020-04-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431c191614eb, moduleTitle=Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431c191614eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417705, encodeId=5978141e70588, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JAMA Neurol：抗癫痫药物治疗耐受性研究, objectType=article, longId=188792, objectId=928b188e92f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=928b188e92f4, replyNumber=0, likeNumber=66, createdTime=2020-02-27, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=928b188e92f4, moduleTitle=JAMA Neurol：抗癫痫药物治疗耐受性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=928b188e92f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417704, encodeId=6264141e7048c, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Diabetologia：棕榈烯酸与人体胰岛素敏感性、细胞功能和葡萄糖耐受性的关系的纵向分析, objectType=article, longId=187033, objectId=f4d918e0333f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4d918e0333f, replyNumber=0, likeNumber=150, createdTime=2020-02-01, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4d918e0333f, moduleTitle=Diabetologia：棕榈烯酸与人体胰岛素敏感性、细胞功能和葡萄糖耐受性的关系的纵向分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4d918e0333f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417703, encodeId=337d141e70365, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, objectType=article, longId=186953, objectId=314a18695378, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=314a18695378, replyNumber=0, likeNumber=75, createdTime=2020-01-31, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=314a18695378, moduleTitle=急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=314a18695378)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417702, encodeId=470a141e702dc, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后, objectType=article, longId=180563, objectId=8013180563df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8013180563df, replyNumber=0, likeNumber=71, createdTime=2019-10-07, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8013180563df, moduleTitle=Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8013180563df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417701, encodeId=1b83141e70103, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, objectType=article, longId=179257, objectId=a1d11e925723, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d11e925723, replyNumber=0, likeNumber=46, createdTime=2019-09-12, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d11e925723, moduleTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d11e925723)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417700, encodeId=73bb141e7002f, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Circulation：抑制Notch-1可增强器官移植的耐受性！, objectType=article, longId=179094, objectId=3e2a1e9094a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e2a1e9094a9, replyNumber=0, likeNumber=130, createdTime=2019-09-09, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e2a1e9094a9, moduleTitle=Circulation：抑制Notch-1可增强器官移植的耐受性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e2a1e9094a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417699, encodeId=4d16141e69926, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=评估PCS-499治疗皮脂腺杆菌的安全性和耐受性, objectType=article, longId=178244, objectId=29201e82446e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29201e82446e, replyNumber=0, likeNumber=75, createdTime=2019-08-29, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29201e82446e, moduleTitle=评估PCS-499治疗皮脂腺杆菌的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29201e82446e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417698, encodeId=1868141e6989e, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=2019年国际血栓和止血学会（ISTH）：uniQure的B型血友病基因疗法展现出长达3年的临床益处和耐受性, objectType=article, longId=175019, objectId=5e371e501922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e371e501922, replyNumber=0, likeNumber=68, createdTime=2019-07-10, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e371e501922, moduleTitle=2019年国际血栓和止血学会（ISTH）：uniQure的B型血友病基因疗法展现出长达3年的临床益处和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e371e501922)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

耐受性

2020-05-29

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Ann Rheum Dis：尼达尼布对系统性硬化症相关性间质性肺病的安全性和耐受性

2020-08-23

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet oncol：AML移植后采用索拉菲尼维持治疗的疗效和耐受性

2020-08-13

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Adv Sci ：朱奎/沈建忠团队在抗菌药物耐受性形成机制上取得新进展

2020-08-04

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet：蚊唾液疫苗耐受性及免疫原性研究

2020-06-28

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Ann Oncol：OlympiAD最终的总体存活率和耐受性结果

2020-06-16

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌

2020-06-06

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性

2020-04-27

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性

2020-04-25

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Prostate：镭223进行再治疗的耐受性良好

2020-04-24

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JAMA: 基孔肯雅病毒样颗粒疫苗的安全性和耐受性如何？

2020-04-21

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

EClinicalMedicine：含有贝达奎林和/或德拉米尼的无注射剂治疗方案对青少年有效且耐受性良好

2020-04-11

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析

2020-04-08

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JAMA Neurol：抗癫痫药物治疗耐受性研究

2020-02-27

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Diabetologia：棕榈烯酸与人体胰岛素敏感性、细胞功能和葡萄糖耐受性的关系的纵向分析

2020-02-01

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

急性偏头痛的治疗：STS101在I期临床试验中表现出良好的耐受性

2020-01-31

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后

2019-10-07

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌

2019-09-12

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Circulation：抑制Notch-1可增强器官移植的耐受性！

2019-09-09

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

评估PCS-499治疗皮脂腺杆菌的安全性和耐受性

2019-08-29

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

2019年国际血栓和止血学会（ISTH）：uniQure的B型血友病基因疗法展现出长达3年的临床益处和耐受性

2019-07-10

科室
- - 订阅+
  - 更多科室
工具
服务